WHO WE ARE
We are MediPrint™ Ophthalmics
An emerging San Diego-based clinical stage eye care pharmaceutical company developing and commercializing a proprietary ocular drug delivery portfolio focused on glaucoma, dry eye and ocular allergy initially.
We are using our proprietary MediPrint™ process to develop, clinically test and commercialize drug-eluting, comfort-enhancing contact lenses to treat millions of contact lens wearers worldwide, without the use of eye drops.
We plan to address a variety of eye care unmet needs, all with extensive market opportunities.
We aim to develop and commercialize a deep product pipeline, supported by strong intellectual property, with a highly experienced and successful execution team.
![opthalmic-image-new](https://mediprintlens.com/wp-content/uploads/2021/03/opthalmic-image-new.png)
![aboutus-image](https://mediprintlens.com/wp-content/uploads/2021/03/aboutus-image.jpg)
![icon-ourmission](https://mediprintlens.com/wp-content/uploads/2021/03/icon-ourmission.png)
Our Mission
Our goal is to change the standard of care for successfully delivering ocular drugs to the eye non-invasively. We will use our patented MediPrint™ process to offer a unique value proposition for patients, eye care professionals, strategic partners and payers.
![icon-ourvission](https://mediprintlens.com/wp-content/uploads/2021/03/icon-ourvission.png)
Our Vision
Enhancing vision for life.
Executive Summary
Clinical Stage Eye Care Pharmaceutical Company Focused on Helping Protect Sight
![clinical-stage2](https://mediprintlens.com/wp-content/uploads/2021/03/clinical-stage2.png)
Compelling Unmet Need
40M+ Soft Contact Lens Wearers in the United States
Pipeline Established – Strong I.P.
Glaucoma, Dry Eye, Comfort, Allergy, …
SIGHT-1 Phase 2a Clinical Completed
Glaucoma, five patients, safety endpoints
Execution Team Secured
![execution-team](https://mediprintlens.com/wp-content/uploads/2021/03/execution-team.jpg)
Clear Path to Exit
Phase 3 data in 18 months.